Combining CDK4/6 inhibitors with hormone therapy and what comes next for HR+/HER2- metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, non-interventional real-world study enrolling over 300 patients with HR+/HER2- metastatic or recurrent breast cancer who are receiving or planning to receive CDK4/6 inhibitors combined with endocrine therapy. Investigators will document the effectiveness and safety of the first-line CDK4/6 inhibitor plus endocrine therapy as given in routine practice. After disease progression, physicians will choose subsequent systemic treatments (for example switching CDK4/6 agents plus endocrine therapy, other endocrine regimens, chemotherapy, or targeted therapies), and outcomes and adverse events for those regimens will be recorded. The study aims to capture real-world sequencing decisions and outcomes to inform future practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion criteria:

  * Age ≥ 18 years, postmenopausal or pre/perimenopausal females, or male patients. Female patients must meet one of the following criteria:

    1. Prior bilateral oophorectomy or age ≥ 60 years.
    2. Age \< 60 with natural postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without any other pathological or physiological reasons), and estradiol (E2) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal range.
    3. Pre/perimenopausal females may also be eligible but must be willing to receive LHRH agonist during the study.
  * Pathologically confirmed HR-positive male/female breast cancer patients with evidence of localized recurrence or metastasis, who are not suitable for curative surgery or radiation therapy:

ER-positive and/or PR-positive defined as the proportion of positively stained tumor cells ≥ 1% of all tumor cells (as confirmed by the investigators at the participating center).

* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
* No prior systemic treatment or currently receiving CDK4/6 inhibitors as first-line treatment for advanced disease.
* Reproductive-age females must have a negative serum pregnancy test within 28 days before enrollment and male/female patients must be willing to use a medically approved highly effective contraceptive measure during the study period and up to 1 year after the last dose of investigational drug.
* Non-pregnant or non-lactating females.
* Not concurrently participating in any other ongoing study.
* Patient or legally authorized representative has provided informed consent and is willing and able to comply with the planned visits, study treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

* 1\. Any evidence of severe or uncontrolled systemic illnesses, including uncontrolled hypertension, active bleeding disorders, active infections including hepatitis B, hepatitis C, and human immunodeficiency virus, or severely impaired bone marrow reserve or organ function, including liver and kidney impairment, which, in the investigator's opinion, would greatly alter the risk/benefit balance.
* Patient has not yet recovered from any CTCAE grade ≥ 3 toxicity related to prior treatment at the start of CDK4/6 inhibitor therapy.
* Known history of allergy to CDK4/6 inhibitors, excipients, or drugs with a similar chemical structure or class as CDK4/6 inhibitors.
* Patients deemed unsuitable for enrollment by the investigator.

Where it's running

• Hunan Cancer Hospital
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Ning Xie, Dr.
• Email: xiening@hnca.org.cn
• Phone: +860731-89762161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adherence to Cell Cycle Inhibitors with Endocrine Therapy in Localized High-Risk ER+ Breast Cancer

  This study checks how well patients with localized ER+ breast cancer stick to a combined endocrine therapy and CDK4/6 inhibitor after surgery.

  Recruiting University Hospital, Grenoble · Grenoble · NCT07443774

• Adjuvant abemaciclib plus hormone therapy after locoregional recurrence of HR-positive, HER2-negative breast cancer

  This will test whether adding abemaciclib to standard hormone therapy helps people with HR-positive, HER2-negative breast cancer who have had their first locoregional recurrence.

  Recruiting Phase 3 Japanese Foundation for Cancer Research · Koto-ku, Tokyo · NCT07190443

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Exploring cognitive impairment in breast cancer patients

  This study is trying to see if certain brain changes in young women with breast cancer who are undergoing chemotherapy and hormone therapy can help predict memory and thinking problems, so doctors can choose better treatment plans.

  Recruiting Tang-Du Hospital · Xi'an, Shaanxi · NCT05305092

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.